media: AMP Optimistic in Suit to invalidate Patents on Breast Cancer Genes (BRCA/ovarian....)

Blogger's Note: typical reminder that the Myriad 'breast cancer' genetic testing is not only for breast cancer

AMP Optimistic in Suit to invalidate Patents on Breast Cancer Genes

Expanding the Criteria for BRCA Mutation Testing in Breast Cancer Survivors — JCO abstract (joint Canada/U.S. paper)

Purpose Every year approximately 25% of women diagnosed with breast cancer are younger than 50 years of age, and almost 10% of them have a BRCA mutation. Not all potential carriers are identified by existing criteria for BRCA testing. We estimated the costs and benefits of different BRCA testing criteria for women with breast cancer younger than 50 years.

Conclusion Testing women with TN breast cancers who were younger than 50 years for BRCA mutations is a cost-effective strategy and should be adopted into current guidelines for genetic testing.